NO2120568T3 - - Google Patents

Info

Publication number
NO2120568T3
NO2120568T3 NO08730048A NO08730048A NO2120568T3 NO 2120568 T3 NO2120568 T3 NO 2120568T3 NO 08730048 A NO08730048 A NO 08730048A NO 08730048 A NO08730048 A NO 08730048A NO 2120568 T3 NO2120568 T3 NO 2120568T3
Authority
NO
Norway
Application number
NO08730048A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2120568(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2120568T3 publication Critical patent/NO2120568T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
NO08730048A 2007-02-16 2008-02-15 NO2120568T3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90177207P 2007-02-16 2007-02-16
US96519607P 2007-08-17 2007-08-17
PCT/US2008/054168 WO2008101214A2 (fr) 2007-02-16 2008-02-15 Rapports pharmacologiques fixes dans le traitement des cancers hématopoïétiques et des affections prolifératives

Publications (1)

Publication Number Publication Date
NO2120568T3 true NO2120568T3 (fr) 2018-04-14

Family

ID=39690832

Family Applications (2)

Application Number Title Priority Date Filing Date
NO08730048A NO2120568T3 (fr) 2007-02-16 2008-02-15
NO2022027C NO2022027I1 (no) 2007-02-16 2022-06-30 Combination of daunorubicin and cytarabine

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2022027C NO2022027I1 (no) 2007-02-16 2022-06-30 Combination of daunorubicin and cytarabine

Country Status (20)

Country Link
US (2) US8092828B2 (fr)
EP (3) EP3300601B1 (fr)
JP (1) JP5314600B2 (fr)
KR (2) KR20100014441A (fr)
CN (1) CN105998046A (fr)
AU (1) AU2008216083B2 (fr)
CA (1) CA2678332C (fr)
CY (1) CY1119631T1 (fr)
DK (2) DK3300601T3 (fr)
ES (2) ES2909903T3 (fr)
FR (1) FR22C1034I2 (fr)
HK (1) HK1253378A1 (fr)
HR (1) HRP20220428T3 (fr)
HU (2) HUE058334T2 (fr)
NL (1) NL301185I2 (fr)
NO (2) NO2120568T3 (fr)
PL (2) PL2120568T3 (fr)
PT (2) PT2120568T (fr)
SI (1) SI3300601T1 (fr)
WO (1) WO2008101214A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
US10028912B2 (en) 2011-10-21 2018-07-24 Celator Pharmaceuticals, Inc. Method of lyophilizing liposomes
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015127173A1 (fr) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Composés thérapeutiquement actifs et leurs procédés d'utilisation
WO2015127172A1 (fr) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs procédés d'utilisation
SG10202112699UA (en) 2015-11-11 2021-12-30 Celator Pharmaceuticals Inc Assays and methods for selecting a treatment regimen for a subject with leukemia
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019023873A1 (fr) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 Composition de microparticules nano-lipidiques et composition pharmaceutique pour le traitement de maladies prolifératives du système hématopoïétique
KR20210065962A (ko) * 2018-09-25 2021-06-04 셀라토 파마슈티칼즈, 인코포레이티드 혈액학적 장애의 저강도 치료
WO2020117742A1 (fr) 2018-12-04 2020-06-11 Tien Der Yang Stéréocomplexes pour l'administration d'agents anticancéreux
JP7553453B2 (ja) 2019-03-01 2024-09-18 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383259A1 (fr) * 2002-04-23 2003-10-23 Celator Technologies Inc. Composes synergiques
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
EP1575582A4 (fr) * 2002-11-06 2009-03-11 Wyeth Corp Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique
JP2006507324A (ja) * 2002-11-06 2006-03-02 セルジーン・コーポレーション 骨髄増殖性疾患を治療および管理するための選択的サイトカイン阻害薬を含む組成物およびその使用法
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
CA2564542C (fr) * 2004-04-22 2012-11-27 Celator Pharmaceuticals, Inc. Formulations de combinaison d'agents anthracycliniques et d'analogues de cytidine
SE0402025D0 (sv) 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
EP1976485A4 (fr) 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc Formulations liposomales composees d'amines secondaires et tertiaires et procedes de preparation desdites formulations

Also Published As

Publication number Publication date
PT3300601T (pt) 2022-04-21
NL301185I2 (nl) 2022-07-21
FR22C1034I2 (fr) 2023-06-30
ES2909903T3 (es) 2022-05-10
PL3300601T3 (pl) 2022-05-02
ES2650167T3 (es) 2018-01-17
EP4046640A1 (fr) 2022-08-24
NO2022027I1 (no) 2022-06-30
PT2120568T (pt) 2017-12-04
JP5314600B2 (ja) 2013-10-16
FR22C1034I1 (fr) 2022-09-09
DK3300601T3 (da) 2022-03-21
US20080199515A1 (en) 2008-08-21
WO2008101214A2 (fr) 2008-08-21
HRP20220428T3 (hr) 2022-05-27
KR20100014441A (ko) 2010-02-10
CY1119631T1 (el) 2018-04-04
AU2008216083B2 (en) 2014-02-06
HK1253378A1 (zh) 2019-06-14
JP2010519224A (ja) 2010-06-03
WO2008101214A3 (fr) 2008-11-20
DK2120568T3 (en) 2017-12-11
PL2120568T3 (pl) 2018-03-30
HUE058334T2 (hu) 2022-07-28
KR20150038752A (ko) 2015-04-08
CN105998046A (zh) 2016-10-12
US20100303895A1 (en) 2010-12-02
AU2008216083A1 (en) 2008-08-21
SI3300601T1 (sl) 2022-05-31
US8092828B2 (en) 2012-01-10
HUS2200032I1 (hu) 2022-07-28
AU2008216083A2 (en) 2009-09-24
EP2120568A4 (fr) 2010-04-21
EP2120568B1 (fr) 2017-11-15
EP2120568A2 (fr) 2009-11-25
CA2678332C (fr) 2015-06-02
EP3300601B1 (fr) 2022-01-12
CA2678332A1 (fr) 2008-08-21
EP3300601A1 (fr) 2018-04-04

Similar Documents

Publication Publication Date Title
NO2120568T3 (fr)
CN300727856S (zh) 笔(k38)
CN300730557S (zh) 空气净化机(4)
CN300729267S (zh) 螺钉旋具手柄(h0414d)
CN300902333S (zh) 面料(67)
CN300885513S (zh) 拖鞋(138)
CN300729186S (zh) 菜板(f-t)
CN300728920S (zh) 餐台(ct838)
CN300728871S (zh) 椅子(21)
CN300728723S (zh) 色织腰果提花绸(w803-2)
CN300728505S (zh) 巧克力机(巧克力喷泉机yd-3056)
CN300728409S (zh) 天花灯(6)
CN300728352S (zh) 连椅花架(2)
CN300728290S (zh) 型材(f60隔热平开窗边框)
CN300728090S (zh) 遥控飞机(蓝)
CN300874663S (zh) 切线灯罩(扁桶)
CN300866049S (zh) 童装上衣(ok-y0707)
CN300850942S (zh) 服装(23)
CN300848889S (zh) 桌子
CN300827961S (zh) 插头(cm-01)
CN300727986S (zh) 标签(jmy-030)
CN300827390S (zh) 内包装袋(铁皮石斛)
CN300727945S (zh) 酒瓶标贴
CN300796845S (zh) 平绒面料(43)
CN300726361S (zh) 床(hd1005a)